Get the latest tech news
Cure51 raises a €15M seed round aiming to crack the code on cancer survival
Rather than grimly assembling data about cancer deaths to predict outcomes in treatment, the founders of Cure51 had another idea. They decided to turn the Rather than grimly assembling data about cancer deaths to predict outcomes in treatment, the founders of Cure51 had another idea. They decided to turn the model around 180 degrees. Instead, the company assembles data about long term survivors of cancer, thus hoping to crack the code on what keeps people alive. It’s now raised a €15 million Seed round led by Paris-based Sofinnova Partners. Other investors in this round included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
Instead, the company assembles data about long term survivors of cancer, thus hoping to crack the code on what keeps people alive. The startup will now use the money to build a ‘cohort’ of data to work out why certain cancer patients survive for a long time, even with highly aggressive forms of the disease. Both had previously worked in five well-known oncology centers, such as the Gustave Roussy Institute in Paris and the Vall d’Hebronin Barcelona.
Or read this on TechCrunch
